You just read:

BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

News provided by

BioMarin Pharmaceutical Inc.

Feb 20, 2020, 16:05 ET